# Pancreatic Locally Advanced Irresectable Cancer Ablation

> **NCT03690323** · NA · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 228 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Cancer

## Interventions

- **PROCEDURE:** Radiofrequency ablation (RFA)
- **DRUG:** FOLFIRINOX
- **DRUG:** Nab-paclitaxel plus Gemcitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03690323
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04-07
- **Primary completion:** 2019-11
- **Final completion:** 2020-05
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2018-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690323, "Pancreatic Locally Advanced Irresectable Cancer Ablation". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03690323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*